Myocardial Infarction Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The myocardial infarction therapeutics market size was valued at USD 1.89 billion in 2025 and is estimated to grow from USD 1.98 billion in 2026 to reach USD 2.46 billion by 2031, at a CAGR of 4.52% during the forecast period (2026-2031). This report is Segmented by Therapeutic Class (Antiplatelet, Anticoagulants, Beta-Blockers, and More), Therapy Setting (Emergency and Acute Care Therapy, Reperfusion Therapy, and More), Route of Administration (Oral, Injectable, and More), Distribution (Hospital Pharmacies, Online Pharmacies, and More), Geography (North America, Europe, Asia-Pacific, and More). Forecasts in Value (USD).

Global Myocardial Infarction Therapeutics Market Trends and Insights

Rising Acute Coronary Syndrome and Secondary-Prevention Treatment Demand

More than 800,000 people in the United States experience a heart attack each year, which sustains demand for acute treatment and continuing care. The American Heart Association reported 19.41 million cardiovascular deaths worldwide in 2021, while metabolic risk factors continue to spread in low- and middle-income countries. An acute myocardial infarction commonly leads to a multi-drug regimen that can continue for 12 months or longer. These regimens often include antiplatelets, statins, beta-blockers, and RAAS inhibitors. The 2025 ischemic heart disease burden study reported 254.3 million prevalent cases and 8.99 million deaths in 2021, even as age-standardized mortality rates declined. This gap between a growing case burden and improving survival supports recurring treatment demand in the myocardial infarction therapeutics market.

Guideline Intensification of Antithrombotic and Lipid-Lowering Therapy

The unified ACC, AHA, ACEP, NAEMSP, and SCAI guideline released in February 2025 updated the management of acute coronary syndromes for the first time in more than a decade. The guidance gave Class I, Level A support for adding nonstatin lipid-lowering drugs for eligible acute coronary syndrome patients whose LDL-C remains at or above 70 mg/dL despite maximally tolerated statin therapy. Ezetimibe, evolocumab, alirocumab, inclisiran, and bempedoic acid are included in that approach. The guidance also favors complete revascularization in multivessel disease rather than treatment of only the culprit lesion. It requires a fasting lipid panel 4-8 weeks after treatment begins. These steps can support earlier use of lipid-lowering medicines in hospital formularies across North America and Europe.

Bleeding and Adherence Trade-Offs Limit Full Guideline Uptake

The 2025 acute coronary syndrome guideline addresses bleeding risk when selecting antithrombotic treatment. It limits routine glycoprotein IIb/IIIa inhibitor use to bailout situations and favors radial over femoral access for PCI. These recommendations reflect the bleeding burden associated with dual antiplatelet regimens. The issue is more difficult for patients who have both high ischemic risk and an indication for anticoagulation. Clinicians often de-escalate P2Y12 inhibitor treatment in such cases, which can reduce use of branded agents. Adherence to multi-drug regimens can also fall during the first 6-12 months after discharge, making pharmacist-led support and patient engagement tools important to treatment continuity.

Other drivers and restraints analyzed in the detailed report include:

• Aging, Diabetes, Obesity and Hypertension Expanding the Treatable Population
• Post-MI Heart-Failure Prevention Broadening Cardiometabolic Therapy Use
• Affordability and Reimbursement Gaps Restrict Newer Agents

Segment Analysis

Antiplatelet agents held 34.31% of the myocardial infarction therapeutics market share in 2025. Their position reflects dual antiplatelet therapy requirements that often last 12 months or longer after acute coronary syndrome. The 2025 guideline recommends ticagrelor or prasugrel over clopidogrel for patients managed with PCI. This recommendation supports demand for branded P2Y12 inhibitors despite generic clopidogrel availability. Anticoagulants continue to provide meaningful revenue during acute treatment. Glycoprotein IIb/IIIa inhibitors have a narrower role because current guidance limits them mainly to bailout use.

Lipid-lowering therapies are projected to record a 5.38% CAGR through 2031, making them the fastest-growing therapeutic class in the myocardial infarction therapeutics market. Guideline support for PCSK9 inhibitors in high-risk patients is a key factor behind this outlook. Thrombolytics remain relevant where primary PCI is unavailable, including parts of South America, rural South Asia, and Africa. Beta-blockers and RAAS therapies remain high-volume segments with stable generic prescribing. Their broad use supports consistent demand across geographic markets. The commercial balance is shifting toward treatments that add cardiovascular and kidney protection after the acute event.

Post-discharge secondary prevention therapy captured 38.44% of therapy-setting revenue in 2025. The segment benefits from prescriptions that continue after the patient leaves the hospital. It also benefits from co-prescribing of several medicines and regular refills. Most recurrent MI events occur within 12 months of the index event, supporting the clinical need to maintain treatment. Emergency and acute care therapy has high value per encounter but does not create the same recurring prescription pattern. Inpatient treatment also depends heavily on hospital formulary decisions.

Long-term management therapy is forecast to expand at a 6.52% CAGR through 2031. The growth reflects continued use of PCSK9 inhibitors, SGLT2 inhibitors, and extended antiplatelet therapy. The 2026 real-world study found that 40.6% of eligible acute MI patients began an SGLT2 inhibitor in hospital at discharge. This finding indicates that cardiometabolic management is becoming part of longer-term post-MI care. Reperfusion therapy remains important in the acute setting where door-to-balloon times cannot meet guideline thresholds. Inpatient hospital-based therapy remains centered on antithrombotic and anti-ischemic medicines, where standardized formularies restrict pricing flexibility.

Complete Report Scope:

• By Therapeutic Class
  • Antiplatelet Agents
  • Anticoagulants
  • Glycoprotein IIb/IIIa Inhibitors
  • Beta-Blockers
  • Lipid-Lowering Therapies
  • RAAS and Neurohormonal Therapies
  • Vasodilators and Anti-Ischemic Agents
  • Thrombolytics
  • Other Therapeutic Classes
• By Therapy Setting
  • Emergency and Acute Care Therapy
  • Reperfusion Therapy
  • Inpatient Hospital-Based Therapy
  • Post-Discharge Secondary Prevention Therapy
  • Long-Term Management Therapy
• By Route of Administration
  • Oral
  • Injectable
  • Sublingual
  • Transdermal
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Other Distribution Channels
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 40.61% of the myocardial infarction therapeutics market size in 2025. The region benefits from established STEMI networks, high uptake of branded medicines, and frequent guideline-led changes to prescribing. The February 2025 acute coronary syndrome guidance expanded the role of nonstatin lipid-lowering agents and addressed complete revascularization. These changes can increase medication use during and after an acute event. The United States generates most regional revenue because value-based cardiac care programs support adherence to multi-drug secondary prevention.

Canada contributes through higher adoption of lipid-lowering biologics, while Mexico faces reimbursement conditions that favor generics. A 2025 study found substantial variation in PCI use for STEMI across U.S. hospitals. These care differences support continued quality measurement and more standardized antithrombotic treatment. Europe remains the second-largest region because of public health systems, cardiovascular disease awareness, and clinical research activity. Germany, the United Kingdom, and France are important evidence and treatment markets. France's 2025 clopidogrel reassessment indicates continued pricing scrutiny in Southern Europe.

Asia-Pacific is forecast to grow at a 6.65% CAGR through 2031, the fastest regional rate in the myocardial infarction therapeutics market. China’s Healthy China 2030 strategy, India’s national program for cancer, diabetes, cardiovascular diseases, and stroke, and Japan’s aging population support demand. Japan's 2026 expert consensus on primary PCI for acute coronary syndromes supports broader pharmacological management in hospital settings. China’s regulatory approach creates a localization requirement for imported products while encouraging local drug development. Middle East and Africa and South America remain smaller contributors, but expanding infrastructure supports demand for thrombolytics and generic antiplatelet medicines.

List of Companies Covered in this Report:

• Amgen
• AstraZeneca
• Bayer
• BioCardia, Inc.
• Boehringer Ingelheim
• Bristol-Myers Squibb
• CeleCor Therapeutics
• CellProthera
• CHIESI Farmaceutici S.p.A.
• Daiichi Sankyo
• Eli Lilly and Company
• Faraday Pharmaceuticals
• Idorsia Pharmaceuticals Ltd.
• Johnson & Johnson Innovative Medicine
• Merck
• Mesoblast Limited
• Novartis
• Pfizer
• Recardio
• Regeneron Pharmaceuticals
• Sanofi
• Viatris

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support